These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 20362738)
61. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Factor SA; Molho ES Clin Neuropharmacol; 2004; 27(5):205-7. PubMed ID: 15602098 [TBL] [Abstract][Full Text] [Related]
62. The Importance of Cross-Disciplinary Research: A Commentary on "Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease". Schneider RB; Richard IH Am J Geriatr Psychiatry; 2021 Sep; 29(9):969-971. PubMed ID: 33526370 [No Abstract] [Full Text] [Related]
64. Risperidone treatment for psychosis in end-stage Friedreich's ataxia. Salbenblatt MJ; Buzan RD; Dubovsky SL Am J Psychiatry; 2000 Feb; 157(2):303. PubMed ID: 10671420 [No Abstract] [Full Text] [Related]
65. Quetiapine for Parkinson's Disease psychosis: Evidence-based medicine versus expert belief: A case study. Friedman JH Mov Disord; 2018 Jul; 33(7):1186-1187. PubMed ID: 29644756 [No Abstract] [Full Text] [Related]
66. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096 [No Abstract] [Full Text] [Related]
67. Quetiapine in the management of psychosis secondary to huntington's disease: a case report. Seitz DP; Millson RC Can J Psychiatry; 2004 Jun; 49(6):413. PubMed ID: 15283541 [No Abstract] [Full Text] [Related]
70. Use of risperidone in psychosis associated with Huntington's disease. Madhusoodanan S; Brenner R Am J Geriatr Psychiatry; 1998; 6(4):347-9. PubMed ID: 9793585 [No Abstract] [Full Text] [Related]
71. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Hermanowicz S; Hermanowicz N Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168 [TBL] [Abstract][Full Text] [Related]
73. Risperidone for the treatment of psychosis associated with neurosarcoidosis. Popli AP J Clin Psychopharmacol; 1997 Apr; 17(2):132-3. PubMed ID: 10950486 [No Abstract] [Full Text] [Related]
74. Successful Use of Brexpiprazole for Parkinson's Disease Psychosis Without Adverse Effects: A Case Report. Sanagawa A; Shiraishi N; Sekiguchi F; Akechi T; Kimura K J Clin Psychopharmacol; 2019; 39(6):685-687. PubMed ID: 31688389 [No Abstract] [Full Text] [Related]
75. Risperidone exacerbates Psychosis: A paradoxical phenomenon? Hsu CC; Lin CJ; Lu T; Hu LY Aust N Z J Psychiatry; 2015 Jul; 49(7):669-70. PubMed ID: 25715194 [No Abstract] [Full Text] [Related]
76. Should risperidone be used in Parkinson's disease? Friedman JH; Ott BR J Neuropsychiatry Clin Neurosci; 1998; 10(4):473-5. PubMed ID: 9813797 [No Abstract] [Full Text] [Related]
77. Prognosis of a brief psychotic episode. Furukawa TA Evid Based Ment Health; 2014 Aug; 17(3):81-2. PubMed ID: 25043433 [No Abstract] [Full Text] [Related]
78. Risperidone in chorea and psychosis of Huntington's disease. Erdemoglu AK; Boratav C Eur J Neurol; 2002 Mar; 9(2):182-3. PubMed ID: 11882064 [No Abstract] [Full Text] [Related]
79. Review: Limited evidence that risperidone reduces aggression and conduct problems in the short term in children and adolescents with disruptive behaviour disorders. Weiss MD Evid Based Ment Health; 2013 Aug; 16(3):69. PubMed ID: 23592637 [No Abstract] [Full Text] [Related]
80. Challenges in the management of early psychosis. Haddad PM; Chaudhry IB J Psychopharmacol; 2012 May; 26(5 Suppl):6-7. PubMed ID: 22572072 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]